French medical imaging firm Avicenna.AI has partnered with Blackford, a British software solutions developer, to improve the detection of incidental pulmonary embolism.

Under the partnership, Avicenna.AI will integrate its CE-marked CINA-iPE solution into the Blackford artificial intelligence (AI) platform.

The collaboration is expected to give enhanced capabilities to healthcare professionals to track incidental pulmonary embolism during routine CT scans.

Blackford founder and CEO Ben Panter said: “Blackford is always looking to enhance our AI portfolio to provide healthcare professionals with innovative tools to help enhance clinical efficiency and decision-making.

“We’re delighted to add the CINA-iPE pulmonary embolism solution to our platform, further enhancing our existing trusted relationship with Avicenna.AI.”

With Blackford, medical practitioners can select from a wide range of over 115 AI solutions that are intended to enhance patient outcomes and boost clinical efficiencies.

The Blackford Platform now includes Avicenna’s CINA-iPE technology, giving medical professionals a strong tool for identifying lung blood clots during chest CT angiography.

The French medical imaging firm said only 25% of incidental pulmonary emboli are reported at the initial interpretation, even though incidental pulmonary emboli are frequently found on routine chest CT scans.

The collaboration aims to improve patient outcomes by addressing delayed and missed diagnostic imaging results.

It will especially focus on communities of cancer patients where accidental pulmonary embolism is a leading cause of death.

Avicenna.AI co-founder and CEO Cyril Di Grandi said: “We are thrilled to empower the extensive community of Blackford users with our innovative incidental pulmonary embolism algorithm.

“This global partnership brings healthcare providers closer to a more systematic reporting and treatment of life-threatening pulmonary emboli.”

Established in 2018, Avicenna.AI provides healthcare AI solutions that use deep learning to find, detect, and quantify fatal pathologies from CT medical images. The company’s CINA-iPE tool was launched in February last year.